

February 6, 2024

BSE Limited Floor 25, P. J. Towers Dalal Street, Fort Mumbai - 400 001

Scrip Code: 543271

National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E), Mumbai - 400 051

Trading Symbol: JUBLINGREA

Dear Sirs,

Sub.: Intimation of Investor/ Analyst Meetings

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be physically meeting the following Institutional Investors in Mumbai on 12th & 13th February, 2024, as per details mentioned below. The schedule may undergo change due to exigencies on the part of Investors/ Analysts/Company.

- 1. 360 One
- 2. 3P Investments
- 3. Aditya Birla Capital Asset Management Company Ltd
- 4. Aditya Birla Sun Life Asset Management Company Ltd. PMS
- 5. Aditya Birla Sun Life Insurance Company Ltd
- 6. Aionniosalpha AIF
- 7. Awriga Capital
- 8. East Bridge Capital Management
- 9. Electrum Capital
- 10. EN TRUST FAMILY OFFICE
- 11. ICICI Prudential Asset Management Co. Ltd.
- 12. Invesco Mutual Fund
- 13. Lacuna GmbH
- 14. Max Life Insurance Co. Ltd.
- 15. Motilal Oswal Mutual Fund
- 16. New Mark Capital
- 17. Old Bridge Capital Management
- 18. PNB MetLife India Insurance Company Ltd
- 19. ValueQuest Investment Advisors
- 20. White Oak Capital
- 21. YK2 Partners LLP

A Jubilant Bhartia Company



Jubilant Ingrevia Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel: +91 120 4361000 Fax: +91 120 4234895-96

www.jubilantingrevia.com

Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223 Uttar Pradesh, India CIN : L24299UP2019PLC122657



We are also enclosing the presentation to be used during our interaction.

This is for your information and record.

Thanking you,

Yours faithfully, For Jubilant Ingrevia Limited

Deepanjali Gulati Company Secretary

A Jubilant Bhartia Company



Jubilant Ingrevia Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel: +91 120 4361000 Fax: +91 120 4234895-96 www.jubilantingrevia.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223 Uttar Pradesh, India CIN : L24299UP2019PLC122657





Investor Presentation

February 2024

Jubilant Ingrevia Limited



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

NOTES:

^{1.} The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary

^{2.} Closing Exchange Rate for USD 1 at Rs 83.21 as on December 31, 2023 and Rs 82.17 as on March 31, 2023



- 04

Company Snapshot and Strategic Outlook

Financial Highlights – Q3 & 9M'FY24 - 10

Business Segments Overview - 15

Strategic Initiatives Update - 25

Table of Contents

Company Overview





Jubilant Ingrevia – Overview



40+ years of legacy in Chemicals space, started in 1978



2300+ people with strong leadership team with average 25+ years of experience in Chemicals space



Company overview and presence



Network of 5 state-of-art manufacturing facilities and 3 R&D centres with 100+ scientists

Trusted partner of choice in India, serving 15 of top 20 Global Pharma & 7 of top 10 Global Agrochemical companies.



Global player in Pyridine + Beta with 30+ years experience, **Vitamin B3** with 10+ years experience and **Acetic Anhydride** with 40+ years of experience



Leading Low Cost provider of Pyridine and its value added derivatives, Vitamin B3 and Acetic Anhydride globally



Strong focus on Environment, Sustainability & Governance




2022 ecovadis References Attained 95 percentile globally (CHM Chemicals) in the S&P Global ESG Indices CSA 2022 (Dow Jones Sustainability Index)

Achieved GOLD Sustainability rating in EcoVadis, among the top 7% of global chemical companies


Integrated Business Segments





Jubilant Ingrevia Compass | Purpose, Vision, Capabilities & Values






Company Snapshot

ROW





Nutrition

Executive Leadership Team





Deepak Jain Chief Executive Officer & **Managing Director**

18 years of industry & Consulting experience



Chandan Singh Co-CEO **Chemical Intermediates** 37 years of industry experience



Ambrish Dixit President Speciality Chemicals 22 years of industry experience

Subhra Jyoti Roy Sr. Vice President Agrochemicals 31 years of industry experience



Sr. Vice President Nutrition & Health Ingredients 31 years of industry



Ashish Kumar Sinha Vice President Animal & Human Nutrition & Health Solutions 25 years of industry experience



Prakash Bisht President & **Chief Financial Officer**

34 years of industry experience



Vijay Kumar Srivastava President Chief of Operations

24 years of industry experience



Vinita Koul Sr. Vice President & Head- HR

27 years of industry experience



Prasad Joglekar President & Head – Supply Chain

30 years of industry experience

Leadership team has an average ~ 25+ years of industry experience

Financial Highlights Q3 & 9M FY'24





Chairmen's Message on Q3'FY24 Financial Results





"We are pleased to announce the stable business performance for Q3 amidst the continued challenging market condition.

We are also glad to share that the Board has recommended an interim dividend of 250% i.e. Rs 2.5 per equity share of face value of Re 1 each for the FY'24. This shall result in cash outflow of Rs 39.8 Crore.

The **Agrochemicals sector**, continued to witness sluggish volume pick up globally. Although we believe the inventory de-stocking is in its last leg, the broader challenges to the sector still prevail. Prices globally were under pressure due to excess Chinese supply, at very low prices. Consequently, the agrochemicals intermediate business was affected, both on volume and prices.

In the **Pharmaceutical end-use segment**, we saw steady growth on a YoY basis, resulting in the healthy placement of volumes across the value chain and a stable price environment.

In segments **like Feed, Food, Cosmetics and FMCG**, we successfully placed good volumes in the markets and maintained market share. However, pricing recovery was muted due to aggressive volume push by the competition.

As we draw near to closing the financial year, we are hopeful and continue to have a view that the Agrochemicals segment will witness recovery from H1 of the next financial year. We anticipate signs of pickup in volume by the end of Q4 FY2024.

As a key supplier to global agrochemical companies, we are confident of our role in managing the transition of supply chain sourcing away from China. We are witnessing continuous interest and inflow of inquiries from global agrochemical clients, where these inquiries are also graduating towards advanced stage discussions, and we are confident to meeting their long-term requirements in the times to come.

We kept costs under control through lean initiatives on the input costs front. The energy costs were also reasonably maintained by sourcing coal at optimal prices and other efficiency and mix initiatives.

Driven by robust domestic consumption, we expect the Indian market fundamentals to remain strong and fuel further growth for us.

As we have remained on track towards investments in high-potential categories through our well-defined modular capex plan of Rs 2,000 Crore till FY 2025, we remain focused on delivering structured growth in future."

Key Highlights | Q3'FY24



Product Portfolio mix	 Specialty and Nutrition share of revenue continued its upward traction at 54% in Q3FY24 CDMO, Fine chemicals and Microbial and Nutrition Products grew YoY. 	Green/ESG	 Initiative to increase renewable % in power usage progressing as per plan Bio certification of several products through C-14 tests
Customers	 Strategic partnership discussions initiated with several big customers. 38 new customers acquired in Specialty Chemicals 	Efficiency	 Cost control initiated through Lean Initiatives. Working capital optimized to 20% from 23% in previous quarter. Continued efficiency initiatives focused on productivity, yield and energy cost optimization through digital 'Surge' program
Geographic mix	 Domestic demand remained stable Increased traction from customers in North American markets, while Europe and ROW was sluggish 	People	 25% vacancies filled internally 50% manufacturing workforce is multi-skilled to operate multiple plants Continuous efforts for higher agility & efficiency
Capex plans	 Commissioned Multipurpose Agro intermediates plant during Q3'FY24. Diketene Derivatives and Agro Active plants commissioning in Q4'FY24 	CSR	 One Million Lives touched through Jubilant Bhartia Foundation The Farmer's Development project helped to reduce input costs through the use of technology like the use of Drone and Hydrogel



Particulars ¹	Q3'FY23	Q2'FY24	Q3'FY24	Q-o-Q	Y-o-Y	9M'FY23	9M'FY24	Y-o-Y
Total Revenue	1,158	1,020	966	-5%	-17%	3,628	3061	-16%
Total EBITDA	158	126	104	-17%	-34%	469	356	-24%
EBITDA Margin (%)	14%	12%	11%			13%	12%	
Profit After Tax	92	57	39	-33%	-58%	255	154	-40%
Profit After Tax Margin (%)	8%	6%	4%			7%	5%	
Basic and Diluted EPS (Rs.)	5.8	3.6	2.4	-33%	-58%	16.0	9.7	-40%

- Revenue & EBITDA during the quarter was impacted on account of :
 - Speciality Chemicals: subdued demand in Agrochemicals and lower prices across segments.
 - Chemical Intermediate: Lower volumes of Acetic Anhydride in end-user segments such as Agrochemicals and Paracetamol and higher pressure on contribution margin due to excess capacity given lower demand.



Particulars ¹	FY'2023	Q2'FY2024	Q3'FY2024
Net Debt	312	701	636
Net Debt to Equity	0.12x	0.27x	0.23x
Net Debt to EBITDA	0.54x	1.35x	1.36x
Working Captal to Turnover	17%	23%	20%

• The decrease in Net Debt was on account of working capital release driven by lean initiatives.

Business Segments Overview



Market & Business Highlights | Speciality Chemicals



Market Highlights

- Pharma end-use demand witnessed improvement, however pricing is yet to witness full recovery.
- Agro Chemical slowdown continued on account of pipeline inventory and lower demand of end-use products and the overall market situation remained challenging.
- Although Agro Chemical market witnessed decreasing pressure form de-stocking, the influx of material from surplus Chinese capacities, mitigated the demand and pricing pickup.
- Domestic demand for our products remained steady.
- North American region performed well, whereas muted demand continued in Europe, due to downstream industry slow-down.

Business Highlights

- Overall lower volumes, driven by lower demand for agrochemical end-use, led to pressure on margins
- Share of Pharma End-use improved on a YoY and QoQ basis.
- Overall, we added 38 new customers in the Speciality chemicals business.
- Continued to accumulate new projects in the CDMO business. Looking at strategic partnerships with large global clients on the back of firm enquiries.
- Under Microbial control solutions, the capacity of Pyrithiones is expanded to cater to increased demand. Witnessed continued healthy traction in Pyrithiones business; new customers and product approvals were added.
- Commissioned Multi-purpose Agro Intermediate plant towards the end of Q3'FY24. Further, another Agro Active/ Intermediate plant is to be commissioned in Q4'FY24.
- Diketene plant operated at optimum capacity. The planned expansion of Diketene derivatives to launch 2 more products is on track.
 Commissioning to take place in Q4'FY24.

Business Segment Overview | Speciality Chemicals



70+ Products (Pyridines & Picolines, Cyanopyridines, Piperidines, Aminopyridines, Lutidines; Diketene derivatives)

Globally **among Top 2** in (Pyridine+Beta); Globally **#1** in 18 Pyridine Derivatives Globally **lowest cost producer of Pyridine** offering significant long-term advantage

Serving 15 of top 20 Global Pharma & 7 of top 10 Global Agrochemical companies

Customers Pasa International reach Around 49% expert in

470+ Customers Base70+ Product Offerings

International reach through offices in US, Europe, Japan & China Around **48%** export in regulated markets leading to sustainable revenue



Particulars ¹	Q3'FY23	Q2'FY24	Q3'FY24	Q-o-Q	Y-o-Y	9M'FY23	9M'FY24	Ү-о-Ү
Segment Revenue	468	382	365	-4%	-22%	1,330	1110	-17%
% Share of Overall Revenue	40%	37%	38%			37%	36%	
EBITDA	87	69	55	-20%	-37%	229	181	-21%
% EBITDA Margin	19%	18%	15%			17%	16%	
% Contribution to EBITDA	55%	55%	53%			49%	51%	

- Sluggish demand leading to lower volumes and prices in Agro end-use Products impacted margins significantly
- However, positive traction on the following helped in holding margins at the current level:
 - Increased share of Pharma End-use customers and Improved product mix
 - Positive traction was observed from Diketene derivatives and the microbial control solutions business
 - Gradual and continued reduction in overall energy cost driven by softening of coal prices and better supply mix

Market & Business Highlights | Nutrition & Health Solutions



Market Highlights

- Vitamin demand remained stable during the quarter, however increased competition witnessed from Chinese suppliers.
- Downstream industries continue to maintain lower inventories across regions and Niacinamide pricing remained under pressure.
- Customers seems to be in wait and watch mode due to prices continuing at lower levels.
- We witnessed marginal uptick in prices in the month of January, which we hope shall continue.


Business Highlights

- Nutrition & Health Ingredients (NHI) business witnessed improved demand from Food segment end-use on QoQ and YoY basis. Acquired 12 new customers during the quarter.
- Animal Nutrition & Health Solution (ANHS) business, witnessed demand traction in premixes especially in Mineral premixes, Emulsifiers, and Chromium & Herbal formulations
- ANHS continued focus on increasing market share in Feed segment, acquired 17 new customers during the quarter.
- Prioritising improved share from customers in niche segments i.e. Cosmetics and Food grade resulted in improved volume and revenue from the segment.
- Capex for GMP compliant facility for Food & Cosmetic grade Niancinamide is expected to commission in Q2 of FY25.
- We are working towards the detailed plan for scaled capex for enhancing capacity for Choline & Specialty Premix products and Food Grade Vitamin B4.

Business Segment Overview | Nutrition & Health Solutions



Catering to Varied End Use Industries, ranging from, Personal



"Partner of Choice" to ~460 global customers and has established strong distribution network

Globally, we serve **90+** customers in Cosmetics, **55+** Customers in Dietary supplements & **20+** Customers for Energy Drinks and Breakfast Cereals. Around 44% exports in regulated markets leading to sustainable revenue



Particulars ¹	Q3'FY23	Q2'FY24	Q3'FY24	Q-o-Q	Y-o-Y	9M'FY23	9M'FY24	Y-o-Y
Segment Revenue	132	162	151	-7%	15%	396	516	30%
% Share of Overall Revenue	11%	16%	16%			11%	17%	
EBITDA	9	19	17	-7%	101%	41	53	29%
% EBITDA Margin	7%	12%	12%			10%	10%	
% Contribution to EBITDA	5%	15%	17%			9%	15%	

- Revenue & EBITDA grew on a YoY basis, primarily led by improved demand and price recovery in major products.
- On a QoQ basis Revenue & EBITDA declined on account of lower prices due to Chinese competition.

Market & Business Highlights | Chemical Intermediates



Market Highlights


- Continued to witness muted demand in some of the downstream industries including Agrochemicals and Paracetamol.
- End-Use Industries are maintaining low utilization and lower inventory levels.

Business Highlights

- New global scale, the Acetic Anhydride plant at Bharuch stabilized and operated at optimal utilization level.
- Added 27 new customers during the quarter.
- Maintained market leadership for the Acetic Anhydride in domestic as well as International markets.
- Improved share of domestic sales on YoY and QoQ basis
- Promoting sales with small Indian Manufacturers to augment domestic market share with value added product sales.
- Continued focusing on volumes-based contract with global customers, towards scaling-up volumes.
- Lower demand in Ethyl Acetate continued during the quarter.

Business Segment Overview | Chemical Intermediates







Catering to Multiple End Use Industries with High Growth Potential

Pharma, Agro and Packaging applications are estimated to witness strong growth, through Paracetamol, Acephate, Various APIs and Food Packaging sectors High Growth Potential through Newer End-Use through Wood Acetylation and Polyamide Films of Mobile Phone Screen.



Particulars ¹	Q3'FY23	Q2'FY24	Q3'FY24	Q-o-Q	Y-o-Y	9M'FY23	9M'FY24	Y-o-Y
Segment Revenue	559	476	450	-5%	-19%	1,901	1436	-24%
% Share of Overall Revenue	48%	47%	47%			52%	47%	
EBITDA	71	50	48	-4%	-32%	224	159	-29%
% EBITDA Margin	13%	11%	11%			12%	11%	
% Contribution to EBITDA	45%	40%	46%			48%	45%	

• Revenue and EBITDA for the segment were impacted YoY because of lower realisation in Acetic Anhydride and lower demand and realisations in Ethyl Acetate.



Key Strategic Initiatives

Jubilant Ingrevia Limited


Key Strategic Initiatives



 Biogenic Carbon Content study of our products conducted through C-14 testing and two of the products received 100% rating and several products are 80% and above. Completed Product Carbon Foot-printing (PCF) Assurance of 28 products covering 4 plants.
 Our newly commissioned state-of-the-art R&D lab at Greater Noida is leveraged to : Enhancing our chemistry competency by venturing into electronic chemicals. Building capabilities in fluoride based chemicals and biotech domain. Strengthening our existing capabilities in fine chemicals and pyridine
 Enabling Business Transformation across Manufacturing, Supply Chain & Sales through digital interventions. though digital program 'Surge', Multiple digital initiatives underway towards yield & efficiency improvement, with substantial potential savings through new age digital tools like AI/ML based "Digital Twins" for plants, funnel management for sales Efficient decision making enable through implementation of Data Analytics and Visualization project 'Insight',
 Activated program to Improve power mix towards renewable power, grid power, Power Purchase through exchange in addition to Captive generation. Share of renewable power targeted to increase to 4x by FY2028. Explored Biological treatment for effluent with Government institutes and planned to scale up in FY25
 Through Jubilant Bhartia Foundation Touched 1 Million Lives Healthcare: With the help of Nutritionists and trained fellows organized an awareness programme on Nutrition especially among mothers of malnourished children Education: Created Digital Classrooms in more than 1056 schools and created 70 Microscience Labs. Livelihood: Under Farmer's Development project demonstrated Drone for effective and precise use of Fertilizer and pesticides, Introduced Hydrogel to reduce water use. All these initiatives will reduce the input costs for farmers.

Sustainability





Research Development & Technology (RDT)





Newly setup R&D facility at Greater Noida, equipped with state-of-the-art technology, with advanced fume hoods and analytical machines to ensure efficient synthesis and reaction monitoring in a safer environment.



Key Highlights

3 RDT centers in Noida, Gajraula and Bharuch



35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Grignard etc.
111 highly qualified scientists (23 PhDs)
49 Products in Pipeline for next 4 years

1000 Aromatization	1000s MT		100s MT	MTs			
Aromatization	Oxidation	Sandmeyer	Grignard	Fluorination	Hoffmann Re-arrangement	Bu-Li Reaction	
Vapour Phase Reactions	Ammoxidation,	Bromination	Methylation	Thiol Handling	Methoxylation	Iodination	
Vapour Phase Reactions Chlorination / Photo chlorination	Fermentation	Esterification	Quarternisation	Ethylene Oxide Reaction	N-Formylation	Chiral Synthesis	
	Ketene Technology	Hydrogenation	Chichibabin		De-alkylation		

Efficiencies through Multi Location Manufacturing & Operation Excellence





- Digital Twin Plants to leverage efficiency through Digital means.
- Initiatives to improve power mix towards renewable power, grid power, Power Purchase through exchange in addition to Captive generation.
- Technological upgrades in existing as well as new production boilers to utilize biomass along with Coal.

Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships





....

School Building, Community

Toilet, etc as and when

required

Food and Aariculture Centre of Excellence

Annexure 1- Income Statement | Consolidated



Particulars ¹	Q3'FY23	Q2'FY24	Q3'FY24	QoQ	ΥοΥ	9M'FY23	9M'FY24	YoY
Revenue from operations								
a) Sales/Income from operations	1153	1011	960	-5%	-17%	3611	3040	-16%
b) Other operating income	6	9	6	-33%	5%	17	21	27%
Total revenue from operations	1158	1020	966	-5%	-17%	3628	3061	-16%
Other income	7	9	9	3%	25%	24	26	6%
Total income	1165	1028	975	-5%	-16%	3652	3087	-15%
Expenses								
a) Cost of materials consumed	617	473	501	6%	-19%	2003	1553	-22%
b) Purchases of stock-in-trade	33	14	18	29%	-45%	107	53	-50%
c) Changes in inventories of finished goods,								
stock-in-trade and work-in progress	-40	18	-11	-158%	-73%	-176	-42	-76%
d) Employee benefits expense	82	103	101	-2%	23%	257	298	16%
e) Finance costs	7	13	15	20%	125%	16	39	146%
f) Depreciation and amortisation expense	30	34	34	1%	14%	92	100	9%
g) Other expenses:								
- Power and fuel expense	179	133	111	-17%	-38%	559	404	-28%
- Others	136	160	150	-6%	11%	433	466	8%
Total expenses	1044	949	920	-3%	-12%	3291	2871	-13%
Profit before share of loss of an associate (3-4)	122	80	55	-31%	-55%	361	216	-40%
Share of loss of an associate	0	0	0			0	0	-240%
Profit before tax	122	80	55	-31%	-55%	361	216	-40%
Tax expense								
- Current tax	10	13	12	-6%	14%	59	41	-30%
- Deferred tax charge	20	10	5	-52%	-76%	47	21	-55%
Net profit for the period/year	92	57	39	-33%	-58%	255	154	-40%
Earnings per share of ₹ 1 each								
Basic (₹)	5.8	3.6	2.4			16.1	9.7	
Diluted (₹)	5.8	3.6	2.4			16.0	9.7	

1. All figures are in Rs Crore unless otherwise stated.

Expenses covered in Other expenses include i) Consumption of stores and spares and packing materials. ii) Repairs and maintenance, iii) Freight & forwarding (including ocean freight). iv) Others

31

Annexure II: Income Statement Segmental – Q3 & 9M'FY24



Particulars ¹	Q3'FY23	Q2'FY24	Q3'FY24	QoQ (%)	YoY (%)	9M'FY23	9M'FY24	YoY (%)
Total Revenue from Operations	1,158	1,020	966	(5%)	(17%)	3,628	3,061	(16%)
Speciality Chemicals	468	382	365	(4%)	(22%)	1,330	1,110	(17%)
Nutrition & Health Solutions	132	162	151	(7%)	15%	396	516	30%
Chemical Intermediates	559	476	450	(5%)	(19%)	1,901	1,436	(24%)
Reported EBITDA	158	126	104	(17%)	(34%)	469	356	(24%)
Speciality Chemicals	87	69	55	(20%)	(37%)	229	181	(21%)
Nutrition & Health Solutions	9	19	17	(7%)	101%	41	53	29%
Chemical Intermediates	71	50	48	(4%)	(32%)	224	159	(29%)
Unallocated Corporate (Expenses)/Income	-9	-12	-16	-	-	-24	-37	-
ΡΑΤ	91.53	57	39	(33%)	(58%)	255	154	(40%)
EPS	5.8	3.6	2.4	(33%)	(58%)	16.0	9.7	(40%)
Reported EBITDA Margins	13.7%	12.4%	10.8%			12.9%	11.6%	
Speciality Chemicals	18.7%	18.1%	15.1%			17.2%	16.3%	
Nutrition & Health Solutions	6.6%	11.5%	11.5%			10.4%	10.3%	
Chemical Intermediates	12.7%	10.6%	10.7%			11.8%	11.0%	
Net Margin	7.9%	5.6%	4.0%			7.0%	5.0%	

For More Information



Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has over 2,300 employees and serves approximately 1,600 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Jubilant Ingrevia Limited is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.

For more information, please visit: <u>www.jubilantingrevia.com</u>

For Investors:

Pavleen Taneja

- Jubilant Ingrevia Limited.
- ☎ Ph: +91 120 436 1000
- E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar, CDR India

- Ph: +91 22 6645 1209
- E-mail: siddharth@cdr-india.com

For Media:

Sudhakar Safaya

- **C** Ph: +91 120 436 1034
- E-mail: sudhakar.safaya@jubl.com

Ryan Marshall

Madison Public Relations

- **Ph: +91 9810047944**
- E-mail: ryan.marshall@madisonpr.in